| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.01 [0.79, 1.29] | | < 1 | | 44% | 2 studies (2/-) | 47.3 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 1.15 [0.54, 2.44] | | < 1 | | 89% | 2 studies (2/-) | 35.9 % | some concern | not evaluable | moderate | important | - |
| DCR | 2.37 [1.73, 3.25] | | > 1 | | 12% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| objective responses (ORR) | 1.85 [0.49, 6.98] | | > 1 | | 68% | 2 studies (2/-) | 81.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| TRAE (any grade) | 0.45 [0.26, 0.76] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.83 [0.21, 3.29] | | < 1 | | 94% | 2 studies (2/-) | 60.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.72 [0.08, 6.23] | | < 1 | | 0% | 2 studies (2/-) | 61.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.72 [0.40, 1.33] | | < 1 | | 0% | 2 studies (2/-) | 85.2 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.73 [0.08, 6.26] | | < 1 | | 0% | 2 studies (2/-) | 61.3 % | some concern | not evaluable | moderate | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.48 [0.21, 1.09] | | < 1 | | 0% | 2 studies (2/-) | 96.0 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 2.06 [0.30, 14.08] | | < 1 | | 5% | 2 studies (2/-) | 23.1 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.96 [0.06, 15.40] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 4.92 [0.54, 44.97] | | < 1 | | 0% | 2 studies (2/-) | 8.0 % | some concern | not evaluable | moderate | non important | - |
| Dry skin TRAE (grade 3-4) | 0.48 [0.04, 5.30] | | < 1 | | 0% | 2 studies (2/-) | 72.5 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.99 [0.05, 18.91] | | < 1 | | 71% | 2 studies (2/-) | 50.4 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.25 [0.04, 1.51] | | < 1 | | 0% | 2 studies (2/-) | 93.4 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
| Hypertension TRAE (grade 3-4) | 2.81 [0.28, 27.87] | | < 1 | | 0% | 2 studies (2/-) | 19.0 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.42 [0.11, 18.62] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 2.25 [0.20, 25.75] | | < 1 | | 0% | 2 studies (2/-) | 25.8 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.27 [0.20, 25.92] | | < 1 | | 0% | 2 studies (2/-) | 25.6 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.82 [0.28, 27.94] | | < 1 | | 0% | 2 studies (2/-) | 18.9 % | some concern | not evaluable | moderate | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.73 [0.08, 6.26] | | < 1 | | 0% | 2 studies (2/-) | 61.3 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.25 [0.04, 1.51] | | < 1 | | 0% | 2 studies (2/-) | 93.4 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 2.24 [0.25, 19.91] | | < 1 | | 24% | 2 studies (2/-) | 23.5 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.66 [0.18, 2.48] | | < 1 | | 0% | 2 studies (2/-) | 72.9 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 1.68 [0.25, 11.08] | | < 1 | | 0% | 2 studies (2/-) | 29.7 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.30 [0.02, 5.18] | | < 1 | | 73% | 2 studies (2/-) | 79.3 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.42 [0.01, 15.25] | | < 1 | | 83% | 2 studies (2/-) | 68.1 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.24 [0.03, 2.14] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
| Pneumonia TRAE (grade 3-4) | 1.92 [0.17, 21.31] | | < 1 | | 0% | 2 studies (2/-) | 29.8 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.72 [0.08, 6.23] | | < 1 | | 0% | 2 studies (2/-) | 61.5 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.96 [0.06, 15.40] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.96 [0.06, 15.40] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.03 [0.05, 21.89] | | < 1 | | 72% | 2 studies (2/-) | 49.3 % | some concern | not evaluable | moderate | non important | - |
| Sepsis TRAE (grade 3-4) | 0.96 [0.06, 15.40] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Skin exfoliation TRAE (grade 3-4) | 1.43 [0.11, 18.70] | | < 1 | | 0% | 2 studies (2/-) | 39.3 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.58 [0.03, 11.22] | | < 1 | | 73% | 2 studies (2/-) | 63.8 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.48 [0.04, 5.30] | | < 1 | | 0% | 2 studies (2/-) | 72.5 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.32 [0.06, 1.58] | | < 1 | | 0% | 2 studies (2/-) | 91.9 % | some concern | not evaluable | moderate | non important | - |
